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Abstract 
Rheumatoid arthritis (RA) is an inflammatory disease characterized by its chronicity and symmetrical pattern of 
involvement. The purpose of the present study was to assess the genotoxic effect of the antitumor necrosis factor-
ɑ agent (Etanercept) in the adult rheumatoid arthritis patients by the mean of a buccal micronucleus cytome assay. 
Buccal smears from a normal mucosa of 30 rheumatoid arthritis patients on Etanercept and 30 healthy subjects 
were taken to apply the buccal micronucleus cytome assay on them. Significantly higher frequencies of 
micronuclei, pyknotic cells and nuclear buds were seen in those patients when compared to controls. In respect to 
these findings, the rheumatoid arthritis patients on Etanercept were showing a higher frequency of the genomic 
damage and cell death biomarkers than the healthy controls which indicates a higher risk of developing pathosis.      
Keywords: Rheumatoid arthritis, genotoxic effect, buccal micronucleus cytome assay. 
 
1. Introduction 
Rheumatoid arthritis (RA) is an inflammatory and autoimmune disease characterized by its chronicity and 
symmetricity, it can manifest at any age predominantly in the females after age of 16, both genetic susceptibility 
and environmental elements (hormones, smoking, infections... etc.) are contributing in the pathogenesis (Hayward 
and Wallace, 2009). 
Several pharmacological agents are used to reduce the  symptoms and to slow down the progression of 
RA, among these drugs, the Disease modifying  anti-rheumatic agents (DMARDs) specially the biological part 
has proven their effectiveness and their better tolerability and less side effects when compared to the conventional 
DMARDs (Gramling and O'Dell, 2012). 
Etanercept (Etan) is a soluble recombinant protein of the human tumor necrosis factor (TNF) receptor 
type 2, bound to the Fc portion of an IgG 1, acts by inhibiting and antagonizing TNF function (Akiyama and 
Mimura, 2006). 
Buccal micronucleus cytome (BMNCyt) assay has assumed to be an easy, quick, cheap cytological assay 
to be used with no invassiveness in the studies that evaluate the ability of different drugs, chemical compounds 
and lifestyle factors to permanently damage the genomic material and cellular morphology in the human (Fenech 
et al., 2011). 
 
2. Methodology 
2.1 Subjects selection: 
A total of 30 RA patients on Etanercept 50 mg/week were included in this study and compared to 30 healthy 
controls matched for age and sex. Patients who were using other drugs or having other autoimmune connective 
tissue disease, those who were smokers or alcoholic and patients who were exposed to the head and neck radiation 
were excluded from the study. Informed consent was gained from all those participants 
 
2.2 Clinical evaluation: 
The RA patients were diagnosed by a rheumatologist according to the American College of 
Rheumatology/European League Against Rheumatism collaborative initiative classification criteria in 2010 
(Aletaha et al., 2010), the clinical disease activity index(CDAI) was calculated for each patient by calculating the 
number of the tender and swollen joints, this number was added to the result of the patient’s/physician’s assessment 
on a visual analogue scale (1-10cm). The score of this index from 2.8-10 is considered as low CDAI, 10-22 as 
moderate CDAI and >22 as being high CDAI (Aletaha et al., 2005). 
 
2.3 Sample collection: 
After recording all the baseline information for the participants, they rinsed their mouth with water before samples 
were taken. A disposable brushes (BAG Lich/Germany) were used to take smears from a normal buccal mucosa 
where the brushes rotated ten times against the inner side of the cheek. The samples were smeared directly to clean, 
dry and labeled microscope slides, slides were fixed immediately with 96% ethanol for 30 min and stained with 
Papanicolaou stain. Two slides were set for every subject. 
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2.4 Slides examination: 
The slides were examined by using the light microscope in a zigzag method after calculating 1,000 cells/slide, the 
scoring based on the criteria described by (Tolbert et al., 1992) to determine the cytological biomarkers frequencies 
(Micronucleated cells, Pyknotic cells, Karyolytic cells, Karyorrhetic cells, Basal cells, Binucleated cells and cells 
with condensed chromatin). The reliability of readings was judged by an inter-examiner calibration with an 
experienced pathologist and an intra-examiner calibration where a total of 10 slides (5 for cases and 5 for controls) 
was re-viewed a month later by the same examiner, the median change observed in all of the examined parameters 
was very small and not statistically significant. 
 
2.5 Statistical analysis: 
Statistical analysis was performed using SPSS 20 and Minitab version 17 software. The Anderson Darling test was 
used to assess the normal distribution of continuous variables. The statistical significance of comparisons between 
the 2 groups was determined by Student’s t-test and one way ANOVA for the normally distributed variables and 
by Mann Whitney U tests for non normally distributed variables. The chi-square test was also used to evaluate the 
relationship between 2 categorical variables, the statistical significance of intra examiner differences was assessed 
by Wilcoxon signed rank test. A Spearman correlation was also used to correlate between variables. 
 
3. Results 
3.1 The demographic data: 
The ages of the participants were ranging from 30-50 years, the mean age of the study group was (42.5) and that 
of the controls was (40.4). The number and percentage of female RA patients was 26(86.7%), while the number 
and percentage of RA male patients was 4(13.3%). This sex distribution matched that of the controls with 
23(76.7%) females and 7(23.3%) males, the P- value for the age and sex distribution was>0.05, therefore; the 
sociodemographic variables were unlikely to confound any detected variances between the study group and 
controls.       
 
3.2 The disease characteristics:  
The disease characteristics in the study group were shown in table 1, the median of disease duration was (6.5) 
years and the median of the treatment’s duration was(2) years. The CDAI mean±SD was (20.4 ± 10.1), The results 
of the CDAI distribution between RA patients showed that (43.3%) of them were presented clinically with high 
disease activity, (40%) of them were with a moderate disease activity and only(16.7%) of them were presented 
with low disease activity. 
Table 1: Disease characteristics of rheumatoid arthritis patients   
Variables  Values 
Disease duration (Median) 6.5 years 
Treatment duration(Median) 2 years 
CADI(Mean±SD) 20.4 ± 10.1 
 
 
 
CADI 
Low No 5 
% 16.7% 
Moderate No 12 
% 40.0% 
High No 13 
% 43.3% 
 
3.3 The cytological findings: 
After calculation of median(inter quartile range) of each parameter, the RA patients on Etan showed a higher 
median of Micronucleated cells (Mn), Pyknotic cells (PK) and nuclear buds(Nbud) when compared to the normal 
control as shown in (table 2, figure 1), the P-values for the statistical differences of those parameters compared to 
the controls were(<0.001 for both Mn and PK) and (0.003) for the Nbud. 
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Table 2: The cytological finding in the controls and RA patients (median and IQR) 
Variables Control (n=30) Etanercept (n=30) P value 
Micronucleated cells 7 (5 – 10) 15 (10 – 30) <0.001 
Pyknotic cells 54 (34 – 76) 89 (64 – 127) <0.001 
Karyorrhectic cells 1 (0 – 2) 1 (0 – 3) 0.357 
Karyolytic cells 0 (0 – 2) 0 (0 – 1) 0.181 
Basal cells 2 (0 – 3) 1 (0 - 2) 0.176 
Nuclear Bud 0 (0 - 0) 0 (0 – 1) 0.003 
Binucleated cells 0 (0 - 0) 0 (0 – 1) 0.185 
Condensed chromatin 0 (0 - 0) 0 (0 - 0) - 
Mann Whitney U test 
 
 
 
 
 
 
 
 
 
 
Figure1: The cytological findings, a:Micronucleus, b:Pyknotic nucleus, c:Nuclear bud. 
 
3.4 The correlation between the cytological findings and the CDAI: 
Univariant linear regression was used to assess the correlation between the cytological findings and the CDAI, the 
results revealed no association between them (P>0.05) as in the table 3. 
Table 3: Univariate linear regression of various variables according to CADI 
Variable Correlation coefficient DF P- value 
Micronucleated cells 0.129 0.473 0.497 
Pyknotic cells 0.048 0.066 0.8 
Karyorrhectic cells -0.336 3.568 0.069 
Karyolytic cells 0.051 0.073 0.788 
Basal cells -0.189 1.035 0.318 
Nuclear Bud 0.255 1.942 0.174 
Binucleated cells -0.032 0.028 0.868 
Condensed chromatin -0.149 0.633 0.433 
DF: degree of freedom = (82,1) 
 
3.5 The correlation between the cytological findings and the treatment duration: 
The median of the duration of the treatment with 50mg/week of Etan was 2 years and no statistical correlation was 
found between the duration of the treatment and the  cytological findings as in table 4. 
Table 4: Correlation between treatment duration and cytological markers 
Variables Spearman correlation P- value 
Micronucleated cells 0.076 0.69 
Pyknotic cells -0.096 0.614 
Karyorrhectic cells 0.019 0.921 
Karyolytic cells -0.148 0.436 
Basal cells -0.307 0.099 
Nuclear Bud -0.215 0.255 
Binucleated cells 0.124 0.515 
Condensed chromatin 0.332 0.073 
Non parametric Spearman correlation 
 
 
 
c 
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4. Discussion 
4.1 Demographic data: 
Rheumatoid arthritis is an age and gender related disease where the middle aged and female patients are the 
commonly affected subjects (Klippel et al., 2008) that matches the results in the present study where the  mean 
age of the RA patients(42.5 years) and the females represented (86.7%) of the patients in the study group. 
 
4.2 Disease characteristics: 
The meadian of the disease duration was(6.5) years, the studies found that the increased duration of RA could 
reduce the responsiveness to the treatments used, increased the joint destruction along with unstable disease 
activity scores and reduced functional abilities, as well as increasing the risk of developing the complications such 
as coronary-artery calcification, increased risk of infections because of the perminant changes in thier immune 
system and prolonged use of immune supressive drugs like the steroids and biologicals(Listing et al., 2012; 
Welsing et al., 2001).  
The median of Etan treatment was 2 years, which was similar to the duration of Etan treatment in the 
study of (Moreland et al., 2001) who cleared that Etan medical advantage was safe and well accepted by the 
patients for the period of treatment(a median of 25 months). 
Rheumatoid arthritis involved the inflammation of the joints with the later destruction and impaired 
function, therefore; it is important to assess the extent of the activity of this disease clinically, to measure the 
improvement, response to the present therapies and the necessity of moving to other drugs. The mean of the CDAI 
in RA patients on Etan was (20.4), which was agreed with Furst et al., (2011) who stated that the mean of the 
CDAI was(21.0) for the RA patients presented with mean of disease duration equal to 7.7 years. 
A percentage of (43.3%, 40% and 16.7%) of RA patients were having high, moderate and low CDAI 
values respectively, Furst et al., (2011) showed different CDAI values in the high and moderate subgroups with 
(53% and 28.8% respectively) but the percentage of those with low CDAI was close to our results(18.2%), this 
study stated that the increasing in the disease duration is the main factor that cause more active disease and less 
rate of remission. 
 
4.3 The cytological findings: 
4.3.1 Micronucleated cells: 
Micronuclei are small, chromatin containing bodies outside the main nucleus that may be shaped as a result of 
defects in mitosis or chromosomal breakage (Sabharwal et al., 2015), the results revealed that the median of Mn 
was higher in the RA patients than in the controls (P<0.001), these results were in line with Demirkaya et al., in 
(2009) who studied the genotoxic effect of Etan in Juvenile Idiopathic Arthritis,  who showed an increasing  in the 
DNA damage when compared to the controls. 
Pyknotic cells frequency was higher in RA patients than the controls(P<0.001), PK cells represented a 
marker of the cell death(apoptosis), apoptosis is a regulated process of  cell death used by the body to eliminate 
the cells with a damaged morphology or damaged genetic components, this process may be dysregulated to cause 
either atrophy or uncontrolled growth and cancers, apoptosis mechanism leads to the cell death in different stages, 
where the initial changes of it include beating the cell junctions and membrane structures, later on, the cytoplasm 
shrinks and the nucleus merges into small masses, which later breaks up into fragments and permanently lost 
(Smith and Walker, 2004). 
Nuclear buds(Nbud) just like the micronuclei can reflect a genomic material injury where the increased 
copies of particular DNA fragments (DNA amplification) said to be the main mechanism of their formation. The 
amplified parts of the DNA are usually located at the nucleus boundaries and tend to be rejected by the mean of  
budding during the DNA replication phase of the cell cycle (Fenech et al., 2011). The median of Nbud in the RA 
patients was higher than that in the controls (P=0.003). 
This higher rate of Mn and Nbuds represented the increased rate of the DNA damage produced by the 
drug, this damage can be produced by the RA it self as well, RA as an autoimmune and inflammatory disease can 
contribute to the genotoxicity and cancer formation by the mean of  autoantibodies production (which may attack 
different cytoplasmic and nuclear parts), apoptosis regulation problems and the  disruption in the equilibrium of 
the reactive oxygen species, all the previous causes are sharing the damaging effect produced by RA (karaman et 
al., 2011), therefore; the Mn and Nbuds should be evaluated in an RA patients who are newly diagnosed with no 
treatments. 
Rheumatoid arthritis patients presented with higher cell death rate signified by the higher PK median, 
the increased rate of apoptosis in RA patients can either be related to the chronic inflammation produced by the 
disease itself as the inflammatory cytokines are associated with a damaging effect to the epithelial cells and their 
junction leading to an increased rate of apoptosis to eradicate these damaged cells, therefore; the more active 
inflammation is related to an increased rate of apoptosis and cellular injury (Bruewer et al., 2003) or related to the 
protective action done by the body in an attempt to reduce the irritating and injurious outcome caused by the drugs. 
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The present study demonstrated that the increased frequency of the studied parameters is clearly 
indicating the genotoxic capacity of the drug under study to different extents, the permanent damage produced by 
this drug may or may not cause a mutation, this mutation can either be eliminated by the mean of multiple check 
points and defense mechanisms or passed into the new cells,it is important to know that multiple mutations are 
needed to cause a cancer and the actual formation of the cancerous mass requires a damage at both genetic and 
cellular levels (AshaRani et al., 2009). 
4.3.2 The correlation between the cytological findings and the CDAI: 
It was hypothesised that the increased inflammation which appears clinically in the term of higher CDAI will result 
in a positive correlation with the frequencies of the cytological parameters, but the results of the univariant linear 
regression showed no significant correlation (P>0.05), this may not eliminate the importance of the disease to 
magnitute the damage produced by the drug as the genetic damage produced by the drug under study collectively 
with the effect of chronic inflammation will result in a more apparent outcome, Where the irreversible DNA 
structure changes produced by the genotoxic agent provide an initiation stimulus to develop a cancer and the 
repeated changes in the cellular micro environment produced by the long standing chronic inflammation will 
further promote the cancerous development(Meira et al., 2008).   
4.3.3 The correlation between the cytological findings and treatment duration: 
The goal behind any treatment used in RA is to achieve the total remission or to reach the state of low and 
controlled disease activity where the better quality of life can be gained, the duration of Etan treatment was 
statistically not related to the increasing of the cytological parameters frequencies (P>0.05) ,which may disagree 
with  Demirkaya et al., in (2009), who studied the genotoxic effect of Etan in Juvenile Idiopathic Arthritis,  who 
showed an increasing  in the DNA damage when compared to controls and the damage was more prominent after 
the 90th days, 180th days till the termination of the study, this disagreement may be because the different study 
design or because the small sample size.  
 
5- Conclusion 
The present study showed an increased frequency of the cytological parameters of nuclear damage and cell death 
which may indicate an injurious effect of Etanercept at a cytological level. The collaborated damage produced by 
both the drug as well as the chronic inflammation of RA may increase the chance of developing  different pathosis 
including the cancer.  
 
References 
Akiyama, Y., & Mimura, T. (2006). [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human 
IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor 
linked to an IgG 1-Fc moietry)]. Masui. The Japanese journal of anesthesiology, 55(7), 864-872. 
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., ... & Combe, B. (2010). 2010 
rheumatoid arthritis classification criteria: an American College of Rheumatology/European League 
Against Rheumatism collaborative initiative. Arthritis & Rheumatism, 62(9), 2569-2581. 
Aletaha, D., Ward, M. M., Machold, K. P., Nell, V. P., Stamm, T., & Smolen, J. S. (2005). Remission and active 
disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis & Rheumatism, 
52(9), 2625-2636. 
Asharani, P. V., Hande, M. P., & Valiyaveettil, S. (2009). Anti-proliferative activity of silver nanoparticles. BMC 
cell biology, 10(1), 1. 
Bruewer, M., Luegering, A., Kucharzik, T., Parkos, C. A., Madara, J. L., Hopkins, A. M., & Nusrat, A. (2003). 
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. 
The Journal of Immunology, 171(11), 6164-6172. 
Demirkaya, E., Cok, I., Durmaz, E., Ulutas, O. K., Ayaz, N. A., Besbas, N., & Özen, S. (2010). Genotoxicity of 
anti–tumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis care & research, 
62(1), 73-77. 
Fenech, M., Kirsch-Volders, M., Natarajan, A. T., Surralles, J., Crott, J. W., Parry, J., ... & Thomas, P. (2011). 
Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian 
and human cells. Mutagenesis, 26(1), 125-132. 
Furst, D. E., Pangan, A. L., Harrold, L. R., Chang, H., Reed, G., Kremer, J. M., & Greenberg, J. D. (2011). Greater 
likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from 
the Consortium of Rheumatology Researchers of North America registry. Arthritis care & research, 
63(6), 856-864. 
Gramling, A., & O’Dell, J. R. (2012). Initial management of rheumatoid arthritis. Rheumatic Disease Clinics of 
North America, 38(2), 311-325. 
Hayward, K., & Wallace, C. A. (2009). Recent developments in anti-rheumatic drugs in pediatrics: treatment of 
juvenile idiopathic arthritis. Arthritis research & therapy, 11(1), 1. 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.6, No.16, 2016 
 
15 
Karaman, A., Binici, D. N., & Melikoğlu, M. A. (2011). Comet assay and analysis of micronucleus formation in 
patients with rheumatoid arthritis. Mutation Research/Genetic Toxicology and Environmental 
Mutagenesis, 721(1), 1-5. 
Klippel, J. H., Stone, J. H., & White, P. H. (2008). Primer on the rheumatic diseases. Springer Science & Business 
Media. 
Listing, J., Gerhold, K., & Zink, A. (2012). The risk of infections associated with rheumatoid arthritis, with its 
comorbidity and treatment. Rheumatology, kes305. 
Meira, L. B., Bugni, J. M., Green, S. L., Lee, C. W., Pang, B., Borenshtein, D., ... & Schauer, D. B. (2008). DNA 
damage induced by chronic inflammation contributes to colon carcinogenesis in mice. The Journal of 
clinical investigation, 118(7), 2516-2525. 
Moreland, L. W., Cohen, S. B., Baumgartner, S. W., Tindall, E. A., Bulpitt, K., Martin, R. I. C. H. A. R. D., ... & 
Schiff, M. H. (2001). Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. 
The Journal of Rheumatology, 28(6), 1238-1244. 
Sabharwal, R., Verma, P., Syed, M. A., Sharma, T., Subudhi, S. K., Mohanty, S., & Gupta, S. (2015). Emergence 
of micronuclei as a genomic biomarker. Indian journal of medical and paediatric oncology: official 
journal of Indian Society of Medical & Paediatric Oncology, 36(4), 212. 
Smith, M. D., & Walker, J. G. (2004). Apoptosis a relevant therapeutic target in rheumatoid arthritis?. 
Rheumatology, 43(4), 405-407. 
Tolbert, P. E., Shy, C. M., & Allen, J. W. (1992). Micronuclei and other nuclear anomalies in buccal smears: 
methods development. Mutation Research/Environmental Mutagenesis and Related Subjects, 271(1), 
69-77. 
Welsing, P. M., Van Gestel, A. M., Swinkels, H. L., Kiemeney, L. A., & Van Riel, P. L. (2001). The relationship 
between disease activity, joint destruction, and functional capacity over the course of rheumatoid 
arthritis. Arthritis & Rheumatism, 44(9), 2009-2017. 
 
 
